SCHIRONE, Alessio
 Distribuzione geografica
Continente #
NA - Nord America 297
EU - Europa 132
AS - Asia 57
AF - Africa 1
SA - Sud America 1
Totale 488
Nazione #
US - Stati Uniti d'America 297
IT - Italia 49
PL - Polonia 44
CN - Cina 33
GB - Regno Unito 11
UA - Ucraina 9
TR - Turchia 8
SG - Singapore 7
DE - Germania 6
SE - Svezia 6
BE - Belgio 4
ID - Indonesia 4
VN - Vietnam 4
RO - Romania 2
BR - Brasile 1
FI - Finlandia 1
IN - India 1
SD - Sudan 1
Totale 488
Città #
Warsaw 44
Fairfield 38
Chandler 30
Houston 25
Woodbridge 25
Ann Arbor 22
Ashburn 21
Seattle 18
Jacksonville 14
Wilmington 12
Bologna 10
Cambridge 10
Ferrara 9
Nanjing 9
Izmir 8
Milan 7
New York 6
Princeton 6
Shanghai 6
Beijing 5
Singapore 5
Boardman 4
Brussels 4
Dong Ket 4
Jakarta 4
Guangzhou 3
Baldissero Torinese 2
Frosolone 2
Gualtieri 2
Jinan 2
Nanchang 2
Ottaviano 2
Shenyang 2
Arcene 1
Bacau 1
Brooklyn 1
Changsha 1
Dearborn 1
Delhi 1
Falls Church 1
Hangzhou 1
Helsinki 1
Islington 1
London 1
Los Angeles 1
Mossoró 1
Mountain View 1
Nave 1
Norwalk 1
Redmond 1
Redwood City 1
Rome 1
San Diego 1
San Mateo 1
Wandsworth 1
Washington 1
Zhengzhou 1
Totale 387
Nome #
High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy 159
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 92
Core needle biopsy in invasive breast cancer prognostic/predictive power: concordance with surgical speciemen and impact of immunophenotypes 87
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 73
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study 53
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 26
The Value of Semiquantitative Parameters Derived from 18F-FDG PET/CT for Predicting Response to Neoadjuvant Chemotherapy in a Cohort of Patients with Different Molecular Subtypes of Breast Cancer 19
Impact on the long-term prognosis of FDG PET/CT in luminal-A and luminal-B breast cancer 6
Totale 515
Categoria #
all - tutte 2.715
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.715


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202087 16 2 4 17 4 10 8 6 5 7 2 6
2020/2021140 5 9 7 12 5 10 9 17 15 27 17 7
2021/202254 4 8 5 3 1 1 7 3 2 5 3 12
2022/202376 8 8 3 7 8 10 5 11 10 1 5 0
2023/202476 1 12 4 1 7 11 2 2 1 6 16 13
Totale 515